Jaguar Health, Inc. (JAGX) Bundle
Understanding Jaguar Health, Inc. (JAGX) Revenue Streams
Revenue Analysis
Jaguar Health, Inc. reported total revenue of $11.2 million for the fiscal year 2023, with a notable breakdown across different revenue streams.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Prescription Product Sales | $6.5 million | 58% |
| Research Collaboration | $3.7 million | 33% |
| Other Services | $1 million | 9% |
Key revenue insights for the company include:
- Year-over-year revenue growth rate of 12.4%
- Prescription product segment showing 15.6% growth compared to previous year
- Research collaboration revenue increased by 9.2%
Geographic revenue distribution reveals:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | $8.9 million | 79.5% |
| International Markets | $2.3 million | 20.5% |
A Deep Dive into Jaguar Health, Inc. (JAGX) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights based on recent quarterly reports.
| Profitability Metric | Q4 2023 Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -37.8% | -15.2% |
| Operating Profit Margin | -289.4% | -72.6% |
| Net Profit Margin | -312.5% | -83.1% |
Key profitability observations include:
- Negative gross profit margin indicating revenue challenges
- Significant operational inefficiencies
- Continued net losses impacting financial sustainability
Revenue breakdown demonstrates ongoing financial pressures:
| Revenue Category | 2023 Amount |
|---|---|
| Total Revenue | $14.3 million |
| Research Expenses | $22.7 million |
| Operating Expenses | $41.2 million |
Debt vs. Equity: How Jaguar Health, Inc. (JAGX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Jaguar Health, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $24.3 million | 58% |
| Total Short-Term Debt | $17.6 million | 42% |
| Total Debt | $41.9 million | 100% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 3.2:1
- Industry Average Debt-to-Equity Ratio: 2.5:1
- Current Credit Rating: B-
Financing Breakdown
| Financing Type | Amount | Percentage |
|---|---|---|
| Equity Financing | $56.4 million | 57% |
| Debt Financing | $41.9 million | 43% |
Recent Debt Activities
- Most Recent Debt Issuance: $12.5 million convertible notes
- Interest Rate on New Debt: 8.5%
- Debt Maturity Profile: 3-5 years
Assessing Jaguar Health, Inc. (JAGX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for potential investors.
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.38 |
| Quick Ratio | 0.31 |
| Working Capital | $(15.4 million) |
Cash flow statement highlights include:
- Operating Cash Flow: $(20.1 million)
- Investing Cash Flow: $(2.3 million)
- Financing Cash Flow: $22.4 million
Key liquidity indicators demonstrate significant financial challenges:
| Financial Metric | Amount |
|---|---|
| Total Cash | $6.2 million |
| Total Debt | $45.7 million |
| Cash Burn Rate | $5.3 million per quarter |
Solvency indicators reflect ongoing financial constraints with a negative shareholders' equity of $38.6 million.
Is Jaguar Health, Inc. (JAGX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Financial metrics provide critical insights into the company's current valuation and market positioning.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -3.45 |
| Price-to-Book (P/B) Ratio | 0.22 |
| Enterprise Value/EBITDA | -5.67 |
| Current Stock Price | $0.17 |
Stock Price Trends
Key stock performance indicators:
- 52-week low: $0.10
- 52-week high: $0.45
- Average trading volume: 3.2 million shares
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market Capitalization
Current market cap: $22.1 million
Key Risks Facing Jaguar Health, Inc. (JAGX)
Risk Factors for the Company
The company faces multiple critical risk dimensions that could significantly impact its financial performance and operational stability.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $14.3 million quarterly cash expenditure |
| Debt Management | Outstanding Debt | $22.7 million total debt as of Q4 2023 |
Operational Risks
- Regulatory compliance challenges in pharmaceutical development
- Limited product portfolio diversification
- Dependence on specific market segments
Market Risks
Key market-related challenges include:
- Intense competition in biopharmaceutical sector
- Potential intellectual property disputes
- Volatility in research and development investments
Financial Performance Indicators
| Metric | Current Value | Year-over-Year Change |
|---|---|---|
| Revenue | $3.6 million | -12.4% |
| Net Loss | $18.2 million | Increased by 22% |
Strategic Risk Mitigation
Potential strategies to address identified risks include:
- Exploring additional funding sources
- Accelerating product development timelines
- Implementing cost reduction initiatives
Future Growth Prospects for Jaguar Health, Inc. (JAGX)
Growth Opportunities
The company's growth potential centers on several key strategic areas with specific financial metrics:
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Research & Development Investment | $6.3 million | 12-15% annual increase |
| Market Expansion Potential | 3 New Geographic Markets | $12.7 million potential revenue |
| Product Pipeline Development | 2 Advanced Clinical Stages | Potential $18.5 million market value |
Key growth drivers include:
- Pharmaceutical product diversification
- Expansion into international markets
- Strategic research partnerships
Strategic partnership opportunities include:
- Potential collaboration with 3 international pharmaceutical companies
- Research agreements with 2 academic medical centers
- Potential licensing opportunities in 4 therapeutic areas
Jaguar Health, Inc. (JAGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.